Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTMNI76)

• DTT Name: Calcium-activated potassium channel (KCN)
• Synonyms: Ca-activated K channel
• Gene Name: KCN
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T39078
• Function: Forms a voltage-independent potassium channel that is activated by intracellular calcium. activation is followed by membrane hyperpolarization which promotes calcium influx. The channel is blocked by clotrimazole and charybdotoxin.

Molecular Interaction Atlas (MIA) of This DTT

2 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Charybdotoxin	DMKN345	Scorpion envenoming syndrome	8D43	Approved	[2]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[1]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICA-17043	DMRFY7I	Alzheimer disease	8A20	Phase 2	[3]

20 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide	DMFV76H	Discovery agent	N.A.	Investigative	[3]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	DMQEJVU	Conjunctival fibrosis	9A61.3	Investigative	[4]
2,2,2-tris-(3-fluorophenyl)-acetamide	DMJXAF7	Discovery agent	N.A.	Investigative	[3]
2,2,2-tris-(4-fluorophenyl)-acetamide	DMCZHEN	Discovery agent	N.A.	Investigative	[3]
2,2-bis-(2-fluorophenyl)-2-phenylacetamide	DMDIX40	Discovery agent	N.A.	Investigative	[3]
2,2-bis-(3-fluorophenyl)-2-phenylacetamide	DM6ICRJ	Discovery agent	N.A.	Investigative	[3]
2-(2,4-difluorophenyl)-2,2-diphenylacetamide	DMSND8U	Discovery agent	N.A.	Investigative	[3]
2-(2-chlorophenyl)-2,2-diphenylethanamide	DM60RWZ	Discovery agent	N.A.	Investigative	[3]
2-(3,4-Difluorophenyl)-2,2-diphenylacetamide	DMJKVZ3	Discovery agent	N.A.	Investigative	[3]
2-fluorophenyl-2,2-diphenylacetamide	DMNPGXA	Discovery agent	N.A.	Investigative	[3]
2-trityl-4,5-dihydrooxazole	DMVJORE	Discovery agent	N.A.	Investigative	[3]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[4]
4-fluorophenyl-2,2-diphenylacetamide	DMI03KV	Discovery agent	N.A.	Investigative	[3]
5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one	DMTB91D	Discovery agent	N.A.	Investigative	[4]
Bis(4-fluorophenyl)-2-fluorophenylacetamide	DMO6HWJ	Discovery agent	N.A.	Investigative	[3]
N,N-dimethyl-2,2,2-triphenylacetamide	DM9XZJN	Discovery agent	N.A.	Investigative	[3]
N-ethyl-2,2,2-triphenylacetamide	DMQ3184	Discovery agent	N.A.	Investigative	[3]
N-methyl-2,2,2-triphenylacetamide	DMQGRMO	Discovery agent	N.A.	Investigative	[3]
Triphenylacetic acid methyl ester	DM2VIDK	Discovery agent	N.A.	Investigative	[3]
TRIPHENYLMETHANAMINE	DM3CQIZ	Discovery agent	N.A.	Investigative	[3]

References

• [1] Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
• [2] Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
• [3] Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
• [4] Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.